Gilead Sciences (GILD): Dont Get Too Excited About GS4997 - Leerink
- Record-setting rally pushes on as S&P ends week up 3 percent
- Trump's Cohn Pick Most Bullish Sign Yet for Banks - Cowen
- Unusual 11 Mid-Day Movers: (IDXG) (INVN) (EBS) Higher; (SCON) (DTEA) (DLTH) Lower (more...)
- 21st Century Fox (FOXA) offers to acquire Sky for GBP10.75/share
- Coca Cola (KO) Announces James Quincey to Succeed Muhtar Kent as CEO; Kent to Continue as Chairman
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Leerink Partners analyst, Geoffrey Porges, reiterated his Market Perform rating on shares of Gilead Sciences (NASDAQ: GILD) after investigators presented the results of the phase II trial for Gilead’s GS4997 (now known as selonsertib) in patients with Non Alcoholic Steato-Hepatitis (NASH) at the American Association of the Study of Liver Diseases (AASLD) Meeting in Boston. This relatively small trial has provided the platform for Gilead to advance this compound into large phase III trials in this indication.
On the most recent earnings conference call, the company disclosed that the product has failed in development in other indications such as diabetic nephropathy, and parallel programs in these liver diseases, including simtuzumab, have also been discontinued. However, management’s reaction to GS4997 was very positive and suggested impressive phase II results. The analyst believes the phase II results encouraging signs of disease activity, but at this stage regard the evidence of benefit, and safety and tolerability, as inconclusive. The evidence of effect is persuasive on some endpoints, but unclear on others, and the NASH field is likely to require continued research to refine trial endpoints and to establish some meaningful correlation between those endpoints and clinical benefit for patients. GS4997 also appears to have some tolerability liabilities, which could add to the drug’s limitations in both development and commercialization.
No change to the price target of $89.
Shares of Gilead Sciences closed at $76.75 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Cuts Price Target on Restoration Hardware (RH) to $34 Following 3Q
- Network-1 Technologies (NTIP) Approves Initial 5c Semi-Annual Dividend
- Vail Resorts (MTN) Misses Q1 EPS by 13c
Create E-mail Alert Related CategoriesAnalyst Comments, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!